MGC Pharmaceuticals - £0.7 million Fundraising

Argent BioPharma

14/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230714:nRSN9942Fa&default-theme=true

RNS Number : 9942F  MGC Pharmaceuticals Limited  14 July 2023

14 July 2023

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, RUSSIA, THE REPUBLIC
OF SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. PLEASE SEE
THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE
MARKET ABUSE REGULATION EU NO. 596/2014, AS RETAINED AND APPLICABLE IN THE UK
PURSUANT TO S3 OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO
BE IN THE PUBLIC DOMAIN.

MGC Pharmaceuticals Ltd

 

£0.7 million Fundraising

 

MGC Pharmaceuticals Ltd ("MGC Pharma" or the "Company"), a European based
pharmaceutical company specialising in the production and development of plant
inspired medicines, has conditionally raised £0.65 million (A$1.24 million)
(before expenses) by way of a placing ("Placing") and subscription
("Subscription") of 541,666,667 new ordinary shares of no par value ("Ordinary
Shares") in the capital of the Company ("Fundraising Shares") at a price of
0.12 pence (0.23 cents) per Fundraising Share ("Issue Price").

In addition, the Company has raised £50,000 (A$95,000) from Roby Zomer, CEO
and Managing Director of the Company, pursuant to a convertible loan agreement
("CLA" and, together with the Placing and Subscription, the "Fundraising").
The CLA allows Mr Zomer to provide an investment without requiring advanced
shareholder approval, which would otherwise be required for a direct
subscription.  Additionally, certain members of the Company's management team
are subscribing for Ordinary Shares directly with the Company pursuant to
subscription letters.

The Fundraising is intended to bridge the Company's current general working
capital requirements and will provide a runway of working capital for its
short-term financing obligations. The Company's management are also exploring
additional cost reduction measures that could increase the working capital
runway provided by the Fundraising.

The Directors are assessing a number of potential funding options which would
provide additional funds to the Company. The Directors consider that these
funding discussions are progressing well and are reasonably confident that a
funding solution will be forthcoming, however there is no certainty that the
Company will be able to raise any additional funding.

The Company will apply for quotation of the Fundraising Shares to trading on
the ASX. Quotation of the Fundraising Shares to trading on the ASX is expected
to take place on 14 July 2023. A prospectus ("Prospectus") is required to be
approved by the UK Financial Conduct Authority ("FCA") and published
("Publication") prior to application being made to admit the Fundraising
Shares (represented by Depositary Interests) to the Official List of the FCA
and to trading on the Main Market of London Stock Exchange plc ("London
Admission") and the Directors intend to make an application for London
Admission as soon as practicable after Publication. The Prospectus will,
subject to approval by the FCA, be published on the Company's website.

In addition, the Company has agreed to issue one free attaching option
(exercisable at 0.12 pence (or 0.23 cents) for every Fundraising Share
subscribed for and issued under the Placing and Subscription ("Fundraise
Options"). Each Fundraise Option entitles the holder to subscribe for one
fully paid

Ordinary Share in the capital of the Company at the exercise price during the
exercise period. The Fundraise Options will not be admitted to trading.

The Fundraising Shares will be issued at a price of 0.12 pence (0.23 cents)
each. This price represents a 57% discount from the closing price of 0.28
pence per Ordinary Share on 12 July 2023 on the LSE, and a 62% discount to the
closing price of 0.6 cents on the ASX, being the last practicable trading day
prior to the release of this Announcement. Upon issue, the Fundraising Shares
will represent approximately 13.9% per cent. of the Ordinary Shares then in
issue (assuming that no other Ordinary Shares are issued in the interim).

Following the Fundraising, up to 541,666,667 new Ordinary Shares and
452,358,615 Fundraise Options shall be issued with shareholder approval under
ASX Listing Rule 7.1 (obtained on 29 June 2023) or pursuant to existing
placement capacity as follows:

·      541,666,667 Fundraising Shares with shareholder approval under
ASX Listing Rule 7.1 obtained on 29 June 2023; and

·      452,358,615 Fundraise Options pursuant to existing placement
capacity under ASX Listing Rule 7.1.

It is intended that a further 89,308,052 Fundraise Options will be issued
subject to and conditional upon receiving shareholder approval, which the
Directors will seek at a shareholder meeting details of which will be
announced separately.

Oberon Investments Ltd is acting as broker for the Placing.

Indicative Timetable

The timetable for the Fundraising is detailed in the table below. All dates
are indicative only and subject to change at the discretion of the Board.
Any such change will be announced through a Regulatory News Service.

  Event                                                                 Date
 Issue of Fundraising Shares                                            14 July 2023
 Settlement of Fundraising Shares (represented in the UK by Depositary  14 July 2023
 Interests)
 Fundraising funds received by the Company                              17 July 2023

Rationale for the Placing; Use of funds

The net proceeds raised by way of the Fundraising Shares are expected to be
used for general working capital purposes.

Details of the Fundraising

The Fundraising of 541,666,667 Fundraising Shares at the Issue Price has
raised £0.65 million before expenses for the Company, conditional inter alia
on the quotation of the Fundraising Shares to trading on the ASX.

When issued, the Fundraising Shares will rank pari passu with the existing
Ordinary Shares in the Company. As noted above, participants in the
Fundraising will also receive one Fundraise Option for every Placing Share
subscribed for and issued.

The Company and its UK broker Oberon Investments Ltd ("Oberon") have entered
into a placing agreement pursuant to which Oberon has, subject to certain
conditions, procured subscribers for the Placing Shares at the Issue Price
(the "Placing Agreement"). The Placing Agreement contains provisions entitling
Oberon to terminate the Placing (and the arrangements associated with it) at
any time prior to settlement of the Placing Shares (represented by Depositary
Interests) in CREST in certain circumstances, including in the event of a
breach of the warranties given in the Placing Agreement, the failure of the
Company to comply in any material respect with its obligations under the
Placing Agreement or the occurrence of a force majeure event or a material
adverse change that Oberon decides is materially prejudicial to the outcome of
the Placing. If this right is exercised, the Placing will not proceed and any
monies that have been received in respect of the Placing will be returned to
the applicants without interest. The Company has agreed to pay Oberon, as
broker, a commission and all other costs and expenses of, or in connection
with, the Placing.

Certain members of the Company's management team are amongst those subscribing
for Ordinary Shares directly with the Company pursuant to subscription
letters.

The Fundraising is not being underwritten by Oberon or any other person.

Convertible Loan Agreement

A convertible loan note agreement has been entered into by the Company and
Roby Zomer, pursuant to which Roby Zomer has loaned the Company £50,000,
convertible into Ordinary Shares, subject to receipt of shareholder approval,
for a period of two years at the Issue Price with no interest accruing. In the
event that the loan is not converted into Ordinary Shares within two years of
the date of the agreement, it will become repayable in cash. The Company has
provided certain warranties to Mr Zomer in relation to itself and its
authority to enter into the agreement, and Mr Zomer has provided certain
warranties and covenants to the Company in relation to himself and his loan.

Total voting rights

On issue of the Fundraising Shares, the Company will have 3,892,359,617
Ordinary Shares in issue, each with one voting right. Therefore, the
Company's total number of Ordinary Shares in issue and voting rights will be
3,892,359,617 and this figure may be used by shareholders from issue of the
Placing Shares as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

-Ends-

 

Authorised for release by the board of directors, for further information
please contact:

 MGC Pharmaceuticals Ltd                                                     MGC Pharmaceuticals Ltd

 Roby Zomer                                                                  Arron Canicais / Rowan Harland

 CEO & Managing Director                                                     Joint Company Secretaries

 +61 8 6555 2950                                                             +61 8 6555 2950

 info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)                          info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)
 UK Brokers                                                                  UK Brokers

 Peterhouse Capital                                                          Oberon Capital

 Charles Goodfellow / Lucy Williams / Duncan Vasey                           Adam Pollock / Aimee McCusker

 +44 207 469 0930                                                            +44 203 179 5300

 cg@peterhousecap.com (mailto:cg@peterhousecap.com) / lw@peterhousecap.com   adampollock@oberoninvestments.com (mailto:adampollock@oberoninvestments.com)
 (mailto:lw@peterhousecap.com)                                                 aimeemccusker@oberoninvestments.com
                                                                             (mailto:aimeemccusker@oberoninvestments.com)
 UK IR/PR Advisers

 IFC Advisory

 Graham Herring / Tim Metcalfe / Zach Cohen

 +44 203 934 6630

 mgcpharma@investor-focus.co.uk (mailto:mgcpharma@investor-focus.co.uk)

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
pharmaceutical company, focused on developing and supplying accessible and
ethically produced plant inspired medicines, combining in-house research with
innovative technologies, with the goal of finding or producing treatments to
for unmet medical conditions.

The Company's founders and executives are key figures in the global
pharmaceuticals industry and the core business strategy is to develop and
supply high quality plant inspired medicines for the growing demand in the
medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical
conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise
the development of targeted plant inspired medicines, to be produced in the
Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil, and
Ireland and has a global distribution footprint via an extensive network of
commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma

 

IMPORTANT NOTICES

Inside information

 

Forward Looking Statements

This announcement includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be
identified by the use of forward-looking terminology, including the terms
"believes", "estimates", "plans", "anticipates", "targets", "aims",
"continues", "expects", "intends", "hopes", "may", "will", "would", "could" or
"should" or, in each case, their negative or other variations or comparable
terminology. These forward-looking statements include matters that are not
facts. They appear in a number of places throughout this announcement and
include statements regarding the Directors' beliefs or current expectations.
By their nature, forward-looking statements involve risk and uncertainty
because they relate to future events and circumstances. Investors should not
place undue reliance on forward-looking statements, which speak only as of the
date of this announcement.

Notice to overseas persons

This announcement does not constitute, or form part of, a prospectus relating
to the Company, nor does it constitute or contain any invitation or offer to
any person, or any public offer, to subscribe for, purchase or otherwise
acquire any shares in the Company or advise persons to do so in any
jurisdiction, nor shall it, or any part of it form the basis of or be relied
on in connection with any contract or as an inducement to enter into any
contract or commitment with the Company.

This announcement is not for release, publication or distribution, in whole or
in part, directly or indirectly, in or into Canada, Japan, Russia or the
Republic of South Africa or any jurisdiction into which the publication or
distribution would be unlawful. This announcement is for information purposes
only and does not constitute an offer to sell or issue or the solicitation of
an offer to buy or acquire shares in the capital of the Company in Canada,
Japan, Russia, New Zealand, the Republic of South Africa or any jurisdiction
in which such offer or solicitation would be unlawful or require preparation
of any prospectus or other offer documentation or would be unlawful prior to
registration, exemption from registration or qualification under the
securities laws of any such jurisdiction.  Persons into whose possession this
announcement comes are required by the Company to inform themselves about, and
to observe, such restrictions.

This announcement is not for publication or distribution, directly or
indirectly, in or into the United States.  This announcement is not an offer
of securities for sale into the United States.  The securities referred to
herein have not been and will not be registered under the U.S. Securities Act
of 1933, as amended, and may not be offered or sold in the United States,
except pursuant to an applicable exemption from registration.  No public
offering of securities is being made in the United States.

General

Neither the content of the Company's website (or any other website) nor the
content of any website accessible from hyperlinks on the Company's website (or
any other website) or any previous announcement made by the Company is
incorporated into, or forms part of, this announcement.

References to £ and pence, and A$ and cents, in this announcement are to the
legal currency of the United Kingdom, and of Australia, respectively. A
conversion rate of GBP/AUD 1.91 has been used.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFLFSDDRIVLIV